Trump's administration aims for 'greater transparency' in drug price negotiations
The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under President Donald Trump's administration following criticism from the pharmaceutical industry for the Biden-era law.
What’s Trump Done on Prescription Drug Prices So Far – and What Might Be Next?
An early move by the president has raised questions about what direction his second-term policy on drug costs will take.
Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
US govt looks to bring 'greater transparency' in Medicare drug price negotiations
The U.S. government said on Wednesday it will consider opportunities to "bring greater transparency" for the Medicare drug price negotiation program under President Donald Trump's administration. The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.
Trump Executive Order Signals Drug Pricing Reforms Likely on the Horizon
Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle drug pricing reforms
What will happen to Medicare drug pricing negotiations under Trump?
As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.
Trump administration affirms drug price talks, but will seek input to ‘improve’ program
A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more transparent.
Maine bill aims to protect federal drug pricing program
Lawmakers unveiled the bill that requires pharmaceutical manufacturers to sell certain drugs to care centers and pharmacies in underserved areas at a discount.
CMS aiming for more transparency in drug pricing negotiations
The U.S. Centers for Medicare & Medicaid Services, or CMS, said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated under the Inflation Reduction Act of 2022.
Fierce Healthcare2d
Trump's CMS signals flexibility on Medicare drug price negotiation, sparking new questions for RFK Jr.
The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...
Trump Order Didn’t Reverse All of Biden’s Measures to Lower Drug Costs
President Donald Trump rescinded an executive order issued by former President Joe Biden aimed at finding new models for ...
Where $2 prescription drug prices, Obamacare stand in Trump executive order onslaught
Trump stopped a program that had been in the works and was intended to give Medicare recipients access to more than 100 ...
Trump Order Walks Back Biden-Era Effort To Lower Prescription Drug Prices. Here's Context
Trump rescinded Executive Order 14087, "Lowering Prescription Drug Costs for Americans," which directed Medicare and Medicaid ...
Trump rolls back effort to lower Medicare, Medicaid drug costs
Trump’s executive order halts an effort to cap the copayment for generic medications at $2 for Medicare beneficiaries.